Healthcare provider profile · identity verified

Shyni Subash, MD

Family Practice · WALNUT CREEK, CA · NPI 1306137401

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	310	92
Amlodipine Besylate	Amlodipine Besylate	234	66
Levothyroxine Sodium	Levothyroxine Sodium	181	40
Lisinopril	Lisinopril	155	44
Losartan Potassium	Losartan Potassium	129	41
Metoprolol Succinate	Metoprolol Succinate	112	30
Gabapentin	Gabapentin	104	34
Metformin Hcl Er	Metformin Hcl	99	31
Mirtazapine	Mirtazapine	86	28
Hydrochlorothiazide	Hydrochlorothiazide	79	20
Pantoprazole Sodium	Pantoprazole Sodium	67	22
Omeprazole	Omeprazole	66	25
Rosuvastatin Calcium	Rosuvastatin Calcium	66	21
Trazodone Hcl	Trazodone Hcl	61	21
Famotidine	Famotidine	60	12
Tamsulosin Hcl	Tamsulosin Hcl	59	14
Atenolol	Atenolol	55	15
Albuterol Sulfate Hfa	Albuterol Sulfate	51	33
Pravastatin Sodium	Pravastatin Sodium	49	16
Escitalopram Oxalate	Escitalopram Oxalate	48	suppressed
Metformin Hcl	Metformin Hcl	48	15
Furosemide	Furosemide	44	14
Glipizide Er	Glipizide	39	suppressed
Simvastatin	Simvastatin	38	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	37	14
Allopurinol	Allopurinol	35	11
Carvedilol	Carvedilol	35	suppressed
Fluticasone Propionate	Fluticasone Propionate	35	14
Sertraline Hcl	Sertraline Hcl	34	suppressed
Montelukast Sodium	Montelukast Sodium	32	suppressed
Alendronate Sodium	Alendronate Sodium	31	11
Januvia	Sitagliptin Phosphate	31	suppressed
Synthroid	Levothyroxine Sodium	30	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	29	suppressed
Tramadol Hcl	Tramadol Hcl	29	suppressed
Glipizide	Glipizide	27	suppressed
Clopidogrel	Clopidogrel Bisulfate	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	26	suppressed
Azelastine Hcl	Azelastine Hcl	25	12
Fluoxetine Hcl	Fluoxetine Hcl	25	suppressed
Ozempic	Semaglutide	24	suppressed
Eliquis	Apixaban	23	suppressed
Jardiance	Empagliflozin	23	suppressed
Ezetimibe	Ezetimibe	19	suppressed
Lorazepam	Lorazepam	19	15
Triamcinolone Acetonide	Triamcinolone Acetonide	19	14
Finasteride	Finasteride	18	suppressed
Ibuprofen	Ibuprofen	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	18
Potassium Chloride	Potassium Chloride	18	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Bupropion Xl	Bupropion Hcl	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Lovastatin	Lovastatin	17	suppressed
Meloxicam	Meloxicam	17	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	15	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	15	15
Spironolactone	Spironolactone	15	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Temazepam	Temazepam	14	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	14	suppressed
Azithromycin	Azithromycin	13	13
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Wegovy	Semaglutide	13	suppressed
Donepezil Hcl	Donepezil Hcl	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Mupirocin	Mupirocin	12	12
Nitrofurantoin	Nitrofurantoin Macrocrystal	12	suppressed
Rybelsus	Semaglutide	12	suppressed
Dexlansoprazole Dr	Dexlansoprazole	11	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	11	11
Estradiol	Estradiol	11	suppressed
Fenofibrate	Fenofibrate	11	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error